Aggressive lung cancers harboring KRAS mutations are sensitive to antifolates. Antifolates decrease KRAS gene expression. Large clinical trials needed to investigate antifolate effects in cancers with respect to driving mutations. SAN FRANCISCO — Patients with non-small cell lung cancer who have...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, mutations, meeting, National Cancer Institute, NCI, KRAS, non-small cell lung cancer, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, pemetrexed, antifolates, methotrexate, Dr. Sarah Bacus